Neurocentrx Pharma

Neurocentrx Pharma is a clinical-stage pharmaceutical company based in Edinburgh, Scotland, specializing in the development of treatments for central nervous system (CNS) disorders. The company's core focus is the development of K01, a proprietary oral formulation of ketamine designed to provide a safer and more accessible alternative to existing intravenous and intranasal therapies. K01 is currently being evaluated in Phase 2 clinical trials for treatment-resistant depression (TRD) and is also being investigated for chronic pain management. By utilizing an oral delivery method, Neurocentrx aims to enable at-home administration and reduce the clinical burden associated with traditional ketamine treatments. The company leverages the established safety profile of ketamine while optimizing its pharmacokinetic properties for psychiatric and neurological indications.